AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22361751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 30
Study 20823097 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolofylline 30 mg administered as a 4 h infusion
Number of subjects: 59
Study 17588242 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BoNT‐B) 200 U or more
Number of subjects: 19
Study 17588242 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BoNT‐B) 400 U
Number of subjects: 19
Study 17588242 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BoNT‐B) 800 U
Number of subjects: 19
Study 14762357 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% fraction of inspired oxygen
Number of subjects: 14
Study 14762357 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 14
Study 11443569 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500‐mg tablet twice daily for 3 days
Number of subjects: 89
Study 11443569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 9640487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate plus clarithromycin
Number of subjects: 0
Study 9640487 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole plus clarithromycin
Number of subjects: 0
Study 8113836 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive CSF cytocentrifuge examination with blast cells and normal CSF WBC count
Number of subjects: 64
Study 8113836 — intervention group
Group type: COMPARATOR
Intervention: No blasts in CSF
Number of subjects: 64
Study 3259976 — intervention group
Group type: EXPERIMENTAL
Intervention: Afferent stimulation (TENS/vibration)
Number of subjects: 80
Study 3259976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 3259976 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain relief scale and numerical rating scale
Number of subjects: 80
Study 31728675 — intervention group
Group type: EXPERIMENTAL
Intervention: Single standard dose of sucrose 2 min before heel prick
Number of subjects: 72
Study 31728675 — intervention group
Group type: COMPARATOR
Intervention: Double dose of sucrose 2 min before and 30 s after heel prick
Number of subjects: 72
Study 29705116 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen environment
Number of subjects: 25
Study 29705116 — intervention group
Group type: COMPARATOR
Intervention: Nasal cannula
Number of subjects: 25
Study 27312122 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral product alone (ZO-1)
Number of subjects: 31
Study 27312122 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral product with topical product (ZO-2 + ZT)
Number of subjects: 31
Study 27312122 — intervention group
Group type: COMPARATOR
Intervention: Combination active groups (ZO-2 + ZT)
Number of subjects: 31
Study 27312122 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement alone (ZO-1)
Number of subjects: 31
Study 25615425 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook usage (10 minutes)
Number of subjects: 112
Study 25615425 — intervention group
Group type: COMPARATOR
Intervention: Magazine website (10 minutes)
Number of subjects: 112
Study 25615425 — intervention group
Group type: COMPARATOR
Intervention: Appearance-neutral control website (10 minutes)
Number of subjects: 112
Study 24121608 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB)
Number of subjects: 54
Study 24121608 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 54
Study 24121608 — intervention group
Group type: COMPARATOR
Intervention: Both ACB and FNB
Number of subjects: 54
Study 21906549 — intervention group
Group type: EXPERIMENTAL
Intervention: Special screening and educational intervention (SI)
Number of subjects: 501
Study 21906549 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (CI)
Number of subjects: 501
Study 18754720 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic low-level laser therapy (LLLT)
Number of subjects: 22
Study 18754720 — intervention group
Group type: COMPARATOR
Intervention: Placebo light treatment
Number of subjects: 22
Study 18754720 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic low-level laser therapy (LLLT)
Number of subjects: 22
Study 17056950 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg IV
Number of subjects: 75
Study 17056950 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg IV
Number of subjects: 75
Study 17056950 — intervention group
Group type: COMPARATOR
Intervention: Saline IV (Placebo)
Number of subjects: 75
Study 14616463 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (500 mL diluted with 1500 mL tap water for 2 weeks)
Number of subjects: 20
Study 14616463 — intervention group
Group type: COMPARATOR
Intervention: Tap water (2000 mL for 2 weeks)
Number of subjects: 20
Study 16344024 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of oxymorphone immediate release (IR)
Number of subjects: 122
Study 16344024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 10450717 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic-impregnated catheters (chlorhexidine-silver sulfadiazine)
Number of subjects: 0
Study 8747308 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichlormethiazide (TCT)
Number of subjects: 38
Study 8747308 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine retard (NIF)
Number of subjects: 38
Study 8747308 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (ATN)
Number of subjects: 38
Study 8747308 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril malate (ENP)
Number of subjects: 38
Study 8747308 — intervention group
Group type: COMPARATOR
Intervention: Control period
Number of subjects: 38
Study 2117625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin 1200 mg
Number of subjects: 16
Study 2117625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin 1600 mg
Number of subjects: 16
Study 6452805 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine (100 mg at night, increasing to 200 mg after two weeks)
Number of subjects: 0
Study 6452805 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (75 mg at night, increasing to 150 mg after two weeks)
Number of subjects: 0
Study 6452805 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 0
Study 6452805 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 6452805 — intervention group
Group type: EXPERIMENTAL
Intervention: Both zimelidine and amitriptyline
Number of subjects: 0
Study 31604060 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT) applied at 5 intraoral points for 30 seconds each on one side (laser group)
Number of subjects: 32
Study 31604060 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LLLT applied)
Number of subjects: 32
Study 27865846 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational physiotherapy home exercise intervention
Number of subjects: 20
Study 27865846 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 26507618 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-Dose Combination (FDC) of aspirin and clopidogrel
Number of subjects: 93
Study 26507618 — intervention group
Group type: COMPARATOR
Intervention: Separate Dual Pills (SDP) of aspirin and clopidogrel
Number of subjects: 93
Study 23402546 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 180
Study 23402546 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 180
Study 23402546 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 180
Study 21559284 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous GH bolus
Number of subjects: 8
Study 21559284 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous GH bolus plus an oral glucose load (OGTT)
Number of subjects: 8
Study 21559284 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline plus OGTT
Number of subjects: 8
Study 19264678 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg daily
Number of subjects: 216
Study 19264678 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg daily
Number of subjects: 216
Study 19264678 — intervention group
Group type: COMPARATOR
Intervention: Imatinib <350 mg daily
Number of subjects: 216
Study 17692784 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression profiling (GEP) testing
Number of subjects: 199
Study 17692784 — intervention group
Group type: COMPARATOR
Intervention: Invasive endomyocardial biopsy (EMB)-based strategy
Number of subjects: 199
Study 15138467 — intervention group
Group type: COMPARATOR
Intervention: D1 gastrectomy
Number of subjects: 118
Study 15138467 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 gastrectomy
Number of subjects: 118
Study 11240262 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-field segmented irradiation technique with a planned dose of 78 Gy.
Number of subjects: 5
Study 11240262 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-field segmented irradiation technique.
Number of subjects: 5
Study 11240262 — intervention group
Group type: COMPARATOR
Intervention: Conventional three-field technique.
Number of subjects: 5
Study 9825086 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based practice concepts
Number of subjects: 0
Study 7811315 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 3041816 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone plus tobramycin
Number of subjects: 53
Study 3041816 — intervention group
Group type: COMPARATOR
Intervention: Ticarcillin plus tobramycin
Number of subjects: 53
Study 31081504 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo WiiFit balance training, conducted twice a week for 3 months.
Number of subjects: 1016
Study 31081504 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 1016
Study 28017593 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain spinach
Number of subjects: 103
Study 28017593 — intervention group
Group type: EXPERIMENTAL
Intervention: Creamed spinach
Number of subjects: 103
Study 28017593 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinach ravioli
Number of subjects: 103
Study 28017593 — intervention group
Group type: COMPARATOR
Intervention: Green beans
Number of subjects: 103
Study 25817200 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 37
Study 25817200 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope‐assisted intubation (GS)
Number of subjects: 37
Study 25817200 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraglottic Airway Laryngopharyngeal Tube (SALT)
Number of subjects: 37
Study 23564361 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual circumlaryngeal therapy for 20 minutes
Number of subjects: 16
Study 23564361 — intervention group
Group type: COMPARATOR
Intervention: Complete vocal rest for 20 minutes (Control)
Number of subjects: 16
Study 21943153 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes
Number of subjects: 137
Study 21943153 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 137
Study 21943153 — intervention group
Group type: COMPARATOR
Intervention: Normal glucose tolerance
Number of subjects: 137
Study 21943153 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 137
Study 21943153 — intervention group
Group type: COMPARATOR
Intervention: Females
Number of subjects: 137
Study 19283744 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (IPC)
Number of subjects: 25
Study 19283744 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IPC)
Number of subjects: 25
Study 19283744 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconditioned serum in co-culture
Number of subjects: 25
Study 19283744 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-RI serum co-culture
Number of subjects: 25
Study 18173154 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhixue Baotai Decoction (ZBD)
Number of subjects: 105
Study 18173154 — intervention group
Group type: COMPARATOR
Intervention: Progesterone
Number of subjects: 105
Study 15106888 — intervention group
Group type: EXPERIMENTAL
Intervention: Young adults with a history of suicidal ideation or attempts responding to a hypothetical suicidal peer disclosure.
Number of subjects: 0
Study 15106888 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambiguity of the suicidal disclosure.
Number of subjects: 0
Study 12216436 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidotic fetuses (pH < 7.20)
Number of subjects: 0
Study 12216436 — intervention group
Group type: COMPARATOR
Intervention: Normal fetuses (pH >= 7.20)
Number of subjects: 0
Study 9467116 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarin cases (acute sarin poisoning)
Number of subjects: 18
Study 8551476 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion (300-500 mL bolus and 125-150 mL/h constant drip)
Number of subjects: 68
Study 8551476 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 68
Study 1699835 — intervention group
Group type: EXPERIMENTAL
Intervention: IV albumin (8 g/L of ascitic fluid removed)
Number of subjects: 88
Study 1699835 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dextran-70 (8 g/L of ascitic fluid removed)
Number of subjects: 88
Study 1699835 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 88
Study 507789 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin and probenecid
Number of subjects: 43
Study 507789 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin alone
Number of subjects: 43
Study 29489484 — intervention group
Group type: EXPERIMENTAL
Intervention: 800-kcal, 20 g fat, and 70 g protein diet for 1 week before liver resection
Number of subjects: 60
Study 29489484 — intervention group
Group type: COMPARATOR
Intervention: No special diet
Number of subjects: 60
Study 28395171 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait Variability Index (GVI)
Number of subjects: 100
Study 28395171 — intervention group
Group type: COMPARATOR
Intervention: Control group (implied)
Number of subjects: 100
Study 26121998 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered multiple health behaviour change intervention using acceptance commitment therapy strategies
Number of subjects: 410
Study 26121998 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 410
Study 26121998 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of delivering the intervention
Number of subjects: 410
Study 26121998 — intervention group
Group type: COMPARATOR
Intervention: Health professional visits and medications
Number of subjects: 410
Study 23540546 — intervention group
Group type: EXPERIMENTAL
Intervention: Early aggressive approach
Number of subjects: 645
Study 23540546 — intervention group
Group type: COMPARATOR
Intervention: Initially conservative approach
Number of subjects: 645
Study 23540546 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 645
Study 23540546 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors of all-cause death
Number of subjects: 645
Study 21482566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg iv every 12 h
Number of subjects: 613
Study 21482566 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 1 g iv every 24 h
Number of subjects: 613
Study 21482566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Number of subjects: 613
Study 21482566 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 613
Study 18953579 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based, remote monitoring, advanced symptom management system (ASyMS)
Number of subjects: 112
Study 18953579 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ASyMS)
Number of subjects: 112
Study 16398939 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 5) plus paclitaxel (175 mg/m2) every 3 weeks for 6 cycles
Number of subjects: 120
Study 14988819 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors
Number of subjects: 11945
Study 11335744 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 kcal/fl oz nutrient-enriched postdischarge formula (PDF)
Number of subjects: 125
Study 11335744 — intervention group
Group type: COMPARATOR
Intervention: 20 kcal/fl oz term-infant formula (TF)
Number of subjects: 125
Study 9266288 — intervention group
Group type: EXPERIMENTAL
Intervention: fendol (test)
Number of subjects: 22
Study 9266288 — intervention group
Group type: COMPARATOR
Intervention: ponstan (reference)
Number of subjects: 22
Study 8281983 — intervention group
Group type: EXPERIMENTAL
Intervention: Low P:S high-saturated-fat diet (5% polyunsaturated fatty acids)
Number of subjects: 47
Study 8281983 — intervention group
Group type: COMPARATOR
Intervention: High P:S high-linoleic-acid diet (21% polyunsaturated fatty acids)
Number of subjects: 47
Study 8281983 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 47
Study 3427552 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenylamine (PNL) 200 mg/day
Number of subjects: 26
Study 3427552 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin (ADM) at standard oncological doses up to 550 mg/m2 plus placebo
Number of subjects: 26
Study 30371334 — intervention group
Group type: EXPERIMENTAL
Intervention: statin+niacin
Number of subjects: 2054
Study 30371334 — intervention group
Group type: COMPARATOR
Intervention: statin+placebo
Number of subjects: 2054
Study 27609676 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglion plexus (GP) ablation
Number of subjects: 240
Study 27609676 — intervention group
Group type: COMPARATOR
Intervention: Control (no extra ablation)
Number of subjects: 240
Study 27609676 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 240
Study 25300885 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended self-help program
Number of subjects: 633
Study 25300885 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief screening and feedback intervention
Number of subjects: 633
Study 25300885 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (control group)
Number of subjects: 633
Study 22575031 — intervention group
Group type: EXPERIMENTAL
Intervention: New stone occlusion device
Number of subjects: 59
Study 22575031 — intervention group
Group type: COMPARATOR
Intervention: NTrap occluder
Number of subjects: 59
Study 20230501 — intervention group
Group type: EXPERIMENTAL
Intervention: Deceptive group (n=26)
Number of subjects: 40
Study 20230501 — intervention group
Group type: COMPARATOR
Intervention: Truthful group (n=14)
Number of subjects: 40
Study 18388072 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation (FMD) in COPD patients
Number of subjects: 44
Study 18388072 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-mediated dilation (NMD) in COPD patients
Number of subjects: 44
Study 18388072 — intervention group
Group type: EXPERIMENTAL
Intervention: FMD correlation with FEV1/VC ratio
Number of subjects: 44
Study 18388072 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple linear regression model for FMD
Number of subjects: 44
Study 18388072 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple linear regression model for NMD
Number of subjects: 44
Study 15467660 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 100
Study 15467660 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 100
Study 11467701 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg followed by gemeprost 0.5 mg
Number of subjects: 1224
Study 11467701 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg followed by gemeprost 1.0 mg
Number of subjects: 1224
Study 11467701 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg followed by gemeprost 0.5 mg
Number of subjects: 1224
Study 11467701 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg followed by gemeprost 1.0 mg
Number of subjects: 1224
Study 9873176 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg twice daily)
Number of subjects: 72
Study 9873176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 7973199 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 178
Study 7973199 — intervention group
Group type: COMPARATOR
Intervention: Triazolam 0.25 mg
Number of subjects: 178
Study 2638181 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan toothpaste
Number of subjects: 0
Study 2638181 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% triclosan toothpaste
Number of subjects: 0
Study 2638181 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash (0.2%)
Number of subjects: 0
Study 2638181 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoride/anionic detergent based toothpaste
Number of subjects: 0
Study 2638181 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/zinc formulations
Number of subjects: 0
Study 2638181 — intervention group
Group type: COMPARATOR
Intervention: Triclosan (0.2%)
Number of subjects: 0
Study 267005 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo declared as analgetics
Number of subjects: 0
Study 267005 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo declared as hyperaesthetics
Number of subjects: 0
Study 267005 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with no effect on pain
Number of subjects: 0
Study 267005 — intervention group
Group type: EXPERIMENTAL
Intervention: Time of day (morning vs evening)
Number of subjects: 0
Study 31295649 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial assessment of incisional hernia
Number of subjects: 35
Study 31295649 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Number of subjects: 35
Study 28118272 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric neck extension exercise for 3 months
Number of subjects: 65
Study 28118272 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs for 10 days (same for both groups)
Number of subjects: 65
Study 25712298 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg
Number of subjects: 20